Executive Summary

In May 2026, GSK announced a landmark licensing deal with China’s Suzhou Siran Biotechnology (SiranBio) for SA-030, a novel siRNA oligonucleotide targeting activin receptor–like kinase 7 (ALK7) for cardiometabolic disease. Under the agreement, GSK obtains exclusive global rights (outside mainland China, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize SA-030 (^[1]) (^[2]). GSK pays $55 million upfront and may pay up to $1.005 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on sales (^[3]) (^[4]). SiranBio will complete the ongoing Phase I trial of SA-030 (targeting ALK7 in obese patients) and then transfer development to GSK (^[5]) (^[6]). SA-030 is designed as a long-acting “fat cell–targeted” siRNA that aims to reduce visceral adipose tissue (abdominal fat) while preserving lean mass, improving insulin sensitivity, lipid profiles, and reducing adipose-driven inflammation (^[7]) (^[8]).

This strategic deal fits into GSK’s broader cardiometabolic and oligonucleotide strategy. GSK has positioned cardiometabolic health – particularly addressing residual cardiovascular and metabolic risk in patients with chronic inflammatory diseases of the lung, kidney or liver – as a core focus. As Dr. Kaivan Khavandi (GSK Head of Respiratory, Immunology & Inflammation R&D) summarized, “cardiometabolic disease is the leading cause of death in most patients with chronic inflammatory conditions” and novel complementary approaches (beyond current treatments) are urgently needed (^[9]) (^[10]). SA-030, by targeting ALK7 to reduce visceral fat, exemplifies such a complementary approach. It is intended to complement existing therapies (such as GLP-1 agonists or SGLT2 inhibitors) to further reduce “residual” cardiometabolic risk not addressed by current standard of care (^[11]) (^[12]).

The SA-030 deal is also significant in the context of GSK’s expanding oligonucleotide pipeline. In recent years, GSK has signed multiple partnerships to build a leading RNA-therapy portfolio. Key elements include: bepirovirsen (an Ionis antisense oligo for hepatitis B, now in Phase III) (^[13]); collaborations with Arrowhead (e.g. GSK4532990, a siRNA against HSD17B13 for NASH) (^[14]); Empirico (EMP-012, COPD-targeted siRNA) (^[13]); Frontier Biotech (two preclinical/IND-stage siRNAs for kidney-related conditions) (^[15]); Wave Life Sciences (a broad discovery alliance including an RNA-editing program WVE-006 for alpha-1 antitrypsin deficiency) (^[16]) (^[17]); and others. SA-030 adds a first-in-class ALK7-targeting siRNA to this portfolio, underscoring GSK’s commitment to oligonucleotide therapeutics and its emphasis on genetically validated targets for difficult-to-treat diseases (^[18]) (^[13]).

This report provides an in-depth analysis of the GSK–SiranBio SA-030 deal (May 2026), exploring its scientific, strategic, and market implications. We review the science of ALK7 and visceral adiposity in cardiometabolic disease, detail the terms and context of the licensing agreement, examine GSK’s overall siRNA/oligonucleotide strategy, and analyze how SA-030 fits into the broader obesity/cardiometabolic therapeutic landscape. Multiple data sources and perspectives are integrated, including preclinical and genetic evidence on ALK7, cardiometabolic epidemiology, and comparable biotech case studies. Finally, we discuss future directions and implications for GSK’s pipeline and for patient care. All claims are supported by references to the latest research, industry reports, and official statements.

Introduction and Background

Obesity and related cardiometabolic disorders (diabetes, cardiovascular disease, nonalcoholic steatohepatitis, etc.) are among the world’s leading health challenges. Abdominal (visceral) fat in particular is closely linked to insulin resistance, dyslipidemia, inflammation, and cardiovascular risk (^[19]) (^[20]). Traditional treatments (weight-loss drugs like GLP-1 agonists, SGLT2 inhibitors, statins, blood-pressure medicines) improve outcomes but often leave residual risk. Indeed, recent real-world data show that combining a GLP-1 agonist with an SGLT2 inhibitor reduces major cardiovascular events and renal complications more than either alone (^[21]). However, many patients with chronic liver, lung, or kidney disease still die of cardiovascular causes despite standard care (^[9]) (^[22]), indicating an unmet need for novel “complementary” approachesto cardiometabolic risk.

In parallel, the RNA therapeutics revolution has opened new possibilities. Small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) can “silence” specific genes that are otherwise hard to drug. After Alnylam’s landmark siRNA drugs (e.g. patisiran for TTR amyloidosis) validated the modality, many pharma companies are investing in oligonucleotide pipelines. GSK, traditionally strong in vaccines and small molecules, has recently made aggressive moves into RNA therapies (^[13]) (^[18]). For example, in 2019 GSK licensed an ASO (bepirovirsen) from Ionis to treat hepatitis B (^[23]). In late 2022, GSK announced a collaboration with Wave Life Sciences to co-develop up to eight oligonucleotide programs (including siRNAs and RNA-editing) (^[16]) (^[24]). GSK also acquired various royalties and licenses (from companies like Arrowhead, Empirico, Elsie Biotech) to diversify into multiple disease areas. By 2025, GSK touted that its pipeline was “more than 70% genetically validated,” reflecting heavy emphasis on targets identified through human genetics (^[18]).

GSK’s corporate strategy, under CEO Emma Walmsley, reframed its R&D focus around four core themes (respiratory/immunology, oncology, HIV, and infectious diseases) while also pursuing “opportunities in other therapeutic areas where patient need is high and where our genetic insights apply” (^[25]). GSK has notably deprioritized the direct “obesity drug race” despite much hype; instead it is focusing on the related cardiometabolic complications of obesity and chronic inflammation (^[26]). This includes metabolic liver disease (NASH) and fat-related drivers of morbidity. For example, GSK recently paid $1.2 billion upfront to acquire Boston Pharmaceuticals’ late-stage NASH candidate BRX-101 (an FGF21 analogue) (^[26]). Within this cardiodiometabolic framework, the ALK7-targeting siRNA SA-030 emerges as a novel complement: rather than focusing on central appetite or weight, it aims to reconfigure body fat distribution and reduce the inflammatory signal from visceral fat (“inflammatory adipose tissue driving disease” (^[8])).

At the same time, Chinese biotech innovation is increasingly fueling global pipelines. SiranBio is a Suzhou-based biotech specializing in siRNA drug discovery with proprietary delivery platforms (e.g. its “Stork-X” for extrahepatic delivery) (^[27]). Frontier Biotech (Nanjing) and Empirico (US) are other examples of specialized RNA-focused start-ups. In recent months, GSK struck multiple RNA deals with Chinese partners: in February 2026, GSK licensed two Frontier Biotech siRNAs (with $40M upfront, $963M milestones) (^[15]); in May 2026 came the SiranBio SA-030 deal. These partnerships reflect a biopharma trend of western companies in-licensing innovative assets from Asia.

Table 1 summarizes selected recent oligonucleotide licensing deals for GSK (2019–2026). GSK has repeatedly paid multi-million upfront fees and potential royalties to gain rights to promising RNA therapies (in metabolic, respiratory, infectious, and other domains).

Table 1. Key recent GSK oligonucleotide licensing deals (2019–May 2026). Milestone/total values are approximate. Sources: press releases and news reports (^[3]) (^[4]) (^[15]) (^[13]). (Empirico is majority-US; Frontier and SiranBio are China-based.)

This document proceeds as follows: We first detail the SA-030 licensing deal (terms, parties, asset profile). Next, we examine the biology of ALK7 and adipose tissue in cardiometabolic risk, summarizing preclinical and genetic evidence supporting SA-030. We then analyze GSK’s cardiometabolic strategy, including how SA-030 complements other therapies (GLP-1, SGLT2i, etc.). The report reviews GSK’s broader oligonucleotide pipeline and strategy, placing SA-030 in that context (including other GSK RNA projects and acquisitions). We compare with other deals and market trends, and present data on disease burden and outcomes. Finally, we discuss implications for GSK, patients, and the field, and outline future directions. The analysis draws on scientific literature, clinical data, industry reports, and expert quotes throughout.

The GSK–SiranBio SA-030 Licensing Agreement

On May 6, 2026, Suzhou Siran Biotechnology Co., Ltd. (SiranBio) and GSK Plc announced a global exclusive licensing agreement for SiranBio’s siRNA candidate SA-030 (^[1]) (^[2]). Under the deal, GSK secures worldwide development and commercialization rights to SA-030 excluding Greater China (mainland, Hong Kong, Macau, Taiwan), which presumably remain with SiranBio. The total deal value is up to $1.005 billion in payments: $55 million upfront and the rest in milestone-based payments covering R&D, regulatory and commercial milestones (^[3]) (^[4]). As usual, GSK will also pay tiered royalties on net sales in licensed territories. The timing of payouts aligns with GSK’s development plan. SiranBio retains responsibility for SA-030 through completion of the Phase I trial; thereafter GSK assumes all global clinical development and regulatory submission duties (^[28]) (^[29]).

GSK’s payment structure according to BioPharm International is: “an upfront payment and potential milestone payments totaling up to $1.005 billion”, plus royalties (^[4]). Fierce Biotech similarly noted a $55 million upfront plus up to $1.0 billion in milestones (^[3]) (^[30]). (The slight $5M difference likely arises from taxes or exchange rounding.) Pharmaphorum observed that the deal could “drive the value above $1 billion” (^[2]). Notably, SiranBio stated in Chinese media the total deal value as ¥10.05 billion (~$1.47B) including all milestones (^[31]), which exceeds earlier estimates (perhaps due to including sales milestones beyond development). For our report, we assume the ~$1.0B figure (consistent with Western sources) for development/regulatory milestones, plus royalties.

Under the agreement, SiranBio will complete the ongoing Phase I study of SA-030 (which recently began in obese patients) and will hand the IND to GSK upon Phase I completion (^[5]) (^[29]). After that, GSK will lead all further trials, regulatory filings, and commercialization internationally. The license covers metabolic and vascular diseases related to ALK7 biology. GSK’s head of R&D for Respiratory/Inflammation, Dr. Kaivan Khavandi, emphasized in the press that SA-030 “builds on [GSK’s] emerging pipeline targeting inflammation, fibrosis and vascular drivers of disease” and could improve patient outcomes (^[32]) (^[33]).

At closing, GSK’s Respiratory, Immunology & Inflammation (RI&I) unit will oversee SA-030’s development. Statements from both companies highlight SA-030’s potential. SiranBio’s CEO Dr. Zhiwei Yang said the deal “will solidify [SiranBio’s] foundation by deepening international collaborations” and accelerate converting its pipeline into therapies for “fat and related chronic diseases” (^[34]). GSK noted that cardiometabolic risk (excess visceral fat) is a major unmet driver of mortality in chronic liver, lung, and kidney diseases (^[9]) (^[35]), and positioned SA-030 as addressing that risk.

Pipeline status: SA-030 is in Phase I trials for overweight/obese individuals. ClinicalTrials.gov lists a Phase 1 study (NCTxxx) examining single and multiple dose tolerability and pharmacokinetics of SA-030 in subjects with high abdominal obesity (BMI 30–45) (see Related). The agreed plan is for SiranBio to report Phase I data and then transfer the asset to GSK (expected in late 2026 or 2027). GSK will then design Phase II trials possibly in obese or NAFLD/NASH patients, leveraging its GI/inflammation expertise.

Deal context: This $1.0B deal is among the largest outside-China biotech licensing transactions of 2026 (^[3]) (^[13]). It represents the second multi-hundred-million-dollar siRNA deal GSK has announced in recent months. In October 2025, GSK acquired Empirico’s siRNA (EMP-012) for COPD for up to $745M (^[36]) (^[37]). In February 2026 it licensed Frontier Biotech’s two siRNAs for kidney diseases for up to ~$1.0B (^[15]). These moves signal GSK’s aggressive expansion in RNA therapeutics. Notably, all three deals involve Chinese or Asia-focused innovators (Empirico is US-based but focused on inflammatory diseases; Frontier and SiranBio are China-based), highlighting GSK’s global sourcing.

Financial terms: Specific milestones are not fully disclosed, but based on related announcements: the Frontier and SiranBio deals each have ~$1.0B max. Empirico’s deal included $85M up-front and ~$660M milestones (^[36]) (^[37]). Analogously, SiranBio’s $55M up-front likely covers R&D to Ph1 completion. Remaining milestones likely include phase transitions, regulatory approval, and sales thresholds. GSK spokeswoman quotes have noted tiered royalties without giving rates. Overall, the SA-030 deal aligns financially with blockbuster expectations if the candidate succeeds.

ALK7 and Cardiometabolic Disease

Biological Role of ALK7

Activin receptor–like kinase 7 (ALK7), encoded by the gene ACVR1C, is a serine/threonine kinase of the TGF-β receptor family. ALK7 is predominantly expressed in adipose (fat) tissue and pancreatic islets (^[19]) (^[38]). It binds ligands such as Activin and Growth/Differentiation Factor 3 (GDF3) to activate Smad2/3 signaling. ALK7’s role in physiology has been illuminated by both animal and human genetic studies.

In mice, loss of ALK7 signaling profoundly alters adiposity. Early work showed that global ALK7 knockout mice (on a high-fat diet) are resistant to diet-induced obesity, exhibiting increased fat breakdown (lipolysis) and reduced fat mass (^[19]) (^[39]). For example, Zhao et al. found that neutralizing antibodies against ALK7 in obese mice caused a substantial loss of adipose tissue, improved glucose tolerance, and enhanced muscle fatty acid oxidation (^[19]). These mice showed elevated lipolysis delivering fatty acids to muscle and increased whole-body oxygen consumption (^[40]). Similarly, Satomi Yogosawa et al. reported that ALK7-deficient mice have smaller adipocyte size despite obesity, linked to dysregulated lipid metabolism in adipose tissue (^[41]). In all, inactivating ALK7 leads to net reduction in stored fat and improved metabolic parameters.

Human genetic evidence reinforces ALK7 as a metabolic regulator. Exome sequencing studies have identified rare ACVR1C variants associated with more favorable fat distribution and lower metabolic disease risk (^[42]). Tangseefa et al. (2024) reported three missense variants (N150H, I195T, I482V) in human ACVR1C that correlated with reduced waist-to-hip ratio (adjusted for BMI) (^[43]). Knock-in mice carrying these variants showed graded resistance to high-fat diet–induced obesity: those variants impaired ALK7 signaling in adipocytes, yielding lower weight gain and fat accumulation than wild-type mice (^[44]) (^[45]). In fact, their metabolic improvements (less adiposity and better glucose/insulin measures) tracked with the degree each variant disrupted ALK7 function (^[44]) (^[45]). This suggests partial ALK7 inhibition can confer a leaner phenotype in humans.

Thus, across studies, ALK7 emerges as a “positive regulator” of fat storage in excess nutrition (^[42]) (^[20]). Intact ALK7 signaling seems to limit the activity of lipolysis master regulators (C/EBPα, PPARγ) in mature adipocytes (^[46]). When ALK7 is deficient or blocked, these regulators are unleashed, enhancing fat breakdown (^[47]). As one review noted, “there is a consensus that inactivation of ALK7 signaling reduces fat mass in obese mice” (^[48]). Biologically, ALK7 may have evolved to prevent excessive lipid release and protect tissues from fat overload, but in contemporary obesity its activity becomes maladaptive, promoting visceral fat accumulation and cardiometabolic risk.

Rationale for Targeting ALK7 (SA-030)

Given this biology, inhibiting ALK7 is a promising strategy for obesity and related metabolic diseases. Reducing ALK7 signaling can shrink visceral fat, improve insulin sensitivity and lipid profiles, and diminish adipose-driven inflammation (^[19]) (^[8]). Crucially, many studies indicate ALK7 inhibition preserves lean muscle mass while burning fat, addressing a key goal of obesity therapy: “reducing abdominal fat while preserving lean mass” (^[7]) (^[49]).

Preclinical data support this profile. In SiranBio’s own preclinical models (as summarized in press releases), SA-030 induced long-acting fat reduction via targeted delivery to adipocytes (^[50]) (^[51]). The company notes that fat-cell–targeted siRNA can blunt the chronic inflammation driven by diseased adipose tissue, suggesting not only weight effects but also anti-inflammatory benefits. Indeed, ALK7 blockade in mice reduced the secretion of inflammatory mediators (e.g. IL-1β) from adipose macrophages (^[52]). By contrast, most existing obesity drugs (GLP-1 agonists, etc.) act centrally or on the pancreas; SA-030’s mechanism is complementary, focusing on the adipose tissue niche.

Clinically, excess visceral adipose tissue (VAT) is a major risk factor for cardiovascular and metabolic disease (^[20]). VAT correlates strongly with insulin resistance, dyslipidemia, type 2 diabetes, and atherosclerosis. In the Framingham study, higher VAT independently predicted incident cardiovascular disease (hazard ratio ~1.44) when adjusted for BMI (^[20]). By contrast, subcutaneous fat (SAT) showed no such risk. Reducing VAT can thus yield outsized benefits: GSK and SiranBio posit that lowering VAT will improve insulin sensitivity, plasma lipids, and “fat cell–driven inflammation” (^[53]) (^[8]). Notably, adipose tissue inflammation is now recognized as a driver of systemic metabolic disease (e.g. pro-inflammatory cytokines from fat exacerbate insulin resistance). Thus, SA-030 aims at a validated axis: genetic data show ALK7 variants protect against diabetes (^[19]), and animal models show it induces an anti-diabetic phenotype when blocked (^[19]).

Importantly, combining VAT-targeting with other therapies may yield synergy. GLP-1 agonists and SGLT2 inhibitors both reduce glycemia and cardiovascular risk via independent mechanisms. Recent real-world studies indicate that using a GLP-1 plus an SGLT2 can lower cardiac events by ~30–40% and kidney events by ~50% compared to either drug alone (^[21]). An ALK7 siRNA adds a third mechanism: by physically reducing the “toxicity” of excess visceral fat, it may further cut residual risk. GSK explicitly cites GLP-1 and SGLT2 when discussing combos: their statement notes SA-030 is “complementary” to GLP-1 agonists and SGLT2 inhibitors, providing potential for combination regimens addressing remaining cardiovascular risk (^[11]) (^[12]).

Target Safety and Delivery

ALK7 is primarily expressed in adipocytes and a few other tissues (pancreatic islets, some neurons). Thus, ALK7 inhibition is unlikely to have broad off-target effects. The JCI study showed transient increases in liver triglycerides with ALK7 blockade, but these normalized with long-term treatment (^[54]). GSK and SiranBio will need to monitor liver and glucose effects as SA-030 progresses. Nevertheless, human genetics offers reassurance: carriers of loss-of-function ACVR1C variants have lower metabolic risk and no obvious severe side effects reported (^[55]) (^[42]).

The delivery of SA-030 is also noteworthy. Traditional GalNAc conjugates deliver siRNAs mainly to the liver. SiranBio touts a proprietary “Stork-X” platform for extrahepatic delivery, with claimed success in targeting tissues including fat (^[27]). On its website, SiranBio notes its “multi-tissue” delivery platform has achieved efficient, selective siRNA uptake in muscle, kidney, central nervous system, and fat (^[27]). The company has several obesity-directed programs, implying they have figured out how to shuttle siRNA to adipose tissue. (Details aren’t public, but likely involve novel conjugates or nanoparticles that are adipose-homing.) In short, the platform is explicitly designed to get SA-030 into adipocytes to knock down ALK7. This adipocyte-directed delivery is a key part of SA-030’s “development as a long-acting siRNA with adipocyte-directed delivery” (^[51]). The hope is a low-frequency dosing regimen (perhaps quarterly injections) that silences ALK7 in fat cells over months.

GSK’s Cardiometabolic Strategy and Rationale

Cardiometabolic Risk in Chronic Disease

GSK frames its cardiometabolic strategy around the observation that patients suffering chronic inflammatory diseases often die sooner from cardiovascular causes than from their primary illness. For example, among patients with chronic kidney disease (CKD), cardiovascular events are the leading cause of death. A U.S. analysis found that in nearly 2 million CKD-associated deaths (1999–2020), 31.2% were due to cardiovascular causes, more than any other category (^[22]). Although overall CKD mortality rose, CV deaths slightly declined (thanks to advances), cardiovascular conditions still remain the top killer in CKD. Similarly, many lung disease patients (e.g. COPD) likewise exhibit ischemic heart disease as the final cause of death. GSK notes that “in most patients with chronic inflammatory conditions affecting the liver, lung and kidney, cardiometabolic disease is the leading cause of death” (^[9]) (^[10]). While chronic liver disease deaths are often liver-related, cardiac causes still contribute substantially (e.g. ~10% in NAFLD) (^[56]).

This profile emerges from systemic effects of chronic inflammation: inflammation accelerates atherosclerosis and insulin resistance. Comorbidities cluster. Therefore, GSK’s strategy is to treat these patients holistically: beyond suppressing lung or liver inflammation, also mitigate their elevated cardiovascular risk. In practice, this means combining standard-of-care (glucose control, anti-fibrotic or anti-inflammatory therapy) with drugs that specifically reverse metabolic defects. SA-030 fits here by directly reducing visceral fat-driven pathology.

Complementing Current Therapies

GSK explicitly positions SA-030 as complementary to existing cardiometabolic treatments. Clinical experience shows that GLP-1 agonists (e.g. semaglutide) and SGLT2 inhibitors (e.g. empagliflozin) substantially lower cardiac events, but many patients still suffer heart attacks and strokes. For instance, even after treatment with these drugs, a high-risk diabetic patient’s annual risk of major adverse cardiovascular events (MACE) can remain in the 5–10% range. The recent real-world BMJ study confirms that combining GLP-1 and SGLT2 is better than either alone (^[21]), but the risk does not go to zero. SA-030’s mechanism (reducing intra-abdominal fat and inflammation) addresses residual drivers of risk beyond glucose and hemodynamics. Practically, a patient might receive GLP-1 and SGLT2 therapy to control blood sugar and weight, plus a periodic injection of the ALK7-siRNA to trim visceral adipose tissue and lower LDL/triglycerides and inflammation. Such multidrug regimens could become standard for severely high-risk patients.

GSK’s own literature endorses this synergy. The neuroscience behind obesity suggests that fat reduction on top of weight-loss can preferentially improve metabolic outcomes. SGLT2/GLP1 reduce body weight partly by subcutaneous fat loss, whereas ALK7 targeting is hypothesized to match the “holy grail” of visceral fat loss with lean mass preservation (^[7]). This dual-pronged approach may be especially beneficial in conditions like metabolic dysfunction-associated steatohepatitis (MASH/NASH), where GSK is also developing treatments (e.g. HSD17B13 siRNA and an FGF21 analog). Indeed, reduced visceral fat would likely translate into better liver outcomes. GSK explicitly cites combination therapy in its statements: SA-030 is “being evaluated as a complementary approach to GLP-1 agonists and SGLT2 inhibitors, potentially supporting future combination treatment strategies” (^[12]).

Unmet Needs and Market Opportunity

The unmet medical need is substantial. Obesity and type 2 diabetes prevalence continues to rise globally (affecting hundreds of millions). Many patients either do not respond sufficiently to lifestyle/GLP-1, or cannot tolerate some drugs. Even modest improvements in insulin sensitivity or lipid profile can prevent thousands of adverse events at scale. The market for cardiometabolic therapies (including obesity) is enormous – GLP-1 agonists/modules alone are projected to become multibillion-dollar products. SA-030, if safe and effective, could capture a share of this market, probably as a specialty niche for high-risk patients. Its unique profile as an injectable with durable fat-targeting effect could command premium pricing (similarly to how PCSK9 inhibitors are priced for specific groups). From an investor standpoint, the $1B+ deal implies Blockbuster expectations for SA-030, presuming it reaches the market.

Clinicians recognize the need for novel cardiometabolic drugs. In chronic kidney/liver disease management, standard therapies (statins, ACE inhibitors, etc.) partly close risk gaps, but residual risk remains. Drugs like GLP-1 have shown mortality benefits in diabetics, but adoption is still spreading. A drug that specifically shrinks visceral fat could be transformative. It might be used not only in obesity/diabetes but also in any chronic inflammatory disease where VAT is elevated. GSK’s framing suggests potential use in patients with non-obvious obesity – e.g. patients with fatty liver or lung disease may have modest BMI but still high VAT. Regulatory payors are also focusing on cardiovascular endpoints (CVOT trials are now required), so SA-030 will need to prove it lowers MACE to secure broad usage. Given the precedent of GLP-1 and SGLT2 CVOTs, GSK will likely plan a large outcome study for SA-030 if Phase 2 signals are promising.

In summary, GSK’s option to license SA-030 reflects a strategic bet: that targeting adipose tissue inflammation (via ALK7) is the next frontier in reducing cardiometabolic mortality, especially in combination with existing therapies. It leverages GSK’s strengths (inflammation/vascular expertise) and fills a gap (visceral fat-driven disease) that few approved drugs directly address.

GSK’s Oligonucleotide Pipeline and Strategic Implications

Overview of GSK’s RNA Therapeutics Strategy

Since 2019, GSK has rapidly expanded its investments in RNA-targeted drugs. Their public statements and filings articulate a strategy to integrate genetic medicine insights with a diversified portfolio of oligonucleotides (^[57]) (^[18]). GSK sees multiple advantages of RNA drugs: (1) they can hit “undruggable” targets (like ALK7) that small molecules or antibodies cannot; (2) they can produce durable effects (long-acting silencing); (3) they are broadly applicable across many diseases (^[58]) (^[59]).

Key Assets in Development

By early 2026, GSK’s clinical and preclinical oligonucleotide pipeline includes (among others):

• Bepirovirsen (Ionis-GSK collaboration): An antisense oligonucleotide targeting hepatitis B virus transcripts for HBV cure. Licensed in 2019 (Ionis $25M upfront, exercised post-Phase II). Now in Phase III trials (the “B-Well” studies) as a first-in-class potential HBV functional cure (^[60]). GSK is focusing development on bezirovirsen and has dropped other HBV programs to concentrate on this Ionis-derived asset (^[60]).

• GSK5637608: An siRNA aimed at HBV (exact target unspecified). Mentioned as part of GSK’s HBV portfolio (^[61]). (Likely an internal program or smaller partner deal.)

• GSK3965193: A PAPD5/PAPD7 inhibitor for HBV (small molecule). Beyond our scope, but indicates multi-modal RNA strategy.

• GSK5251738: A TLR8 agonist for HBV (small molecule immune modulator).

These HBV assets show GSK’s broad interest in viral cures (where RNA targets like cccDNA or viral RNA are promising).

• GSK4532990 (formerly ARO-HSD): A siRNA targeting HSD17B13 for nonalcoholic steatohepatitis (NASH). This was licensed from Arrowhead in 2021 (^[14]). A Phase 2b trial (“HORIZON”) for NASH/PFC is ongoing. HSD17B13 was identified via human genetics: loss-of-function alleles in HSD17B13 protect against fatty liver disease (^[62]). GSK pays Arrowhead royalties on success; Arrowhead received at least a $30M milestone when GSK initiated Phase 2 (Apr 2023) (^[63]). The implication is that GSK targets NASH via both FGF21 (see next) and RNA silencing.

• FGF21 Analog (BRX-101 / efimosfermin): An FGF21 biotech acquired via Boston Pharmaceuticals ($1.2B upfront in 2025). Although not an oligo, it’s part of GSK’s metabolic portfolio.

• EM-P012: A siRNA from Empirico for non-T2 inflammatory COPD. GSK paid $85M upfront (October 2025) plus up to $745M total (^[36]) (^[37]). The target is an inflammatory pathway (possibly IL-17 or IL-23 axis) that is independent of eosinophils and smoking status (^[64]). EMP-012 is in a Phase I trial for COPD. GSK’s statement on EMP-012 emphasizes long-acting silencing of a novel COPD target (^[65]). This shows GSK applying siRNA to respiratory diseases (besides NASH).

• SA-030: The ALK7 siRNA (subject of this report), now licensed from SiranBio (^[3]) (^[28]). Entered Phase I in obesity.

• Investigator’s own programs (e.g. GSK532990): A siRNA for MASH (HSD17B13) maybe. (Not confirmed beyond Arrowhead’s phrasing.)

• Frontier Biotech assets: Two siRNAs (one IND-stage, one preclinical) targeting inflammatory kidney diseases (or肾, as per GSK quote) (^[15]). Likely chronic kidney disease or lupus nephritis targets. GSK paid $40M upfront (Feb 2026) for two undisclosed siRNAs from Frontier (^[15]). Frontier will do Chinese Phase I first; GSK obtains global rights for beyond-Phase I (^[15]).

• Wave Life Sciences collaboration (Dec 2022): GSK invested $170M for a four-year discovery alliance and license to Wave’s AATD RNA-editing program (^[16]) (^[66]). Up to 8 new programs will be discovered (some likely preclinical siRNAs or ASOs) (^[16]), plus exclusivity on WVE-006 (an RNA editing AIMer for alpha-1 antitrypsin deficiency in lung+ liver) (^[67]) (^[68]). GSK highlights this collaboration in lung and rare diseases. Notably, Tony Wood (GSK CSO) said WVE-006 (RNA editing AAT) “complements more advanced clinical-phase oligos in [GSK’s] pipeline, including bepirovirsen and GSK4532990” (^[18]). This indicates GSK now has at least 3 preclinical/early oligos for respiratory disease (COPD EMP-012, CRC AAT, plus possibly liver disease via NASH).

• Elsie Biotechnologies platform: GSK has a non-exclusive license to technology from Elsie (RNA upregulation platform). Not much disclosed, but again shows platform strategy.

• Internal R&D: GSK likely has additional small-molecule and possibly genetic therapies in early stages, but recent public focus is on acquired oligos.

Table 2 below summarizes several GSK pipeline assets in RNA therapeutics (selection of those announced or in development):

Table 2. Selected GSK oligonucleotide assets in development (as of May 2026). Includes licensed and internal programs. Phase information from company reports and news (^[24]) (^[14]) (^[13]).

The SA-030 deal is notable because it diversifies GSK’s pipeline into a cardiometabolic/inflammatory indication using siRNA technology – a somewhat new area for large oligo investments. Until recently, GSK’s oligo focus was heavier on infectious diseases (HBV) and liver/fibrotic diseases (NASH, AATD). By licensing SA-030 and Frontier’s kidney assets, GSK is explicitly broadening into inflammation-driven chronic disorders. As Khavandi noted about Frontier’s deal: these siRNAs “add two potential first-in-class therapies with significant opportunity to improve patient outcomes across multiple kidney diseases… well-aligned with our strategic focus on platform technologies and inflammatory-driven disease” (^[71]). SA-030 similarly “adds” a first-in-class approach in the metabolic domain, fitting GSK’s RI&I theme (inflammation plus cardiometabolic).

From a portfolio standpoint, SA-030 sits alongside (and complements) other metabolic deals: as pharmaphorum pointed out, it aligns with GSK’s liver/inflammation pipeline (including efimosfermin and gatuzosiran for MASH) (^[72]). All three (FGF21, HSD17B13 siRNA, ALK7 siRNA) target obesity-related drivers from different angles. This suggests GSK envisions polytherapy for metabolic syndrome: e.g., an FGF21 to improve insulin sensitivity, ALK7 siRNA to shrink visceral fat, etc. The addition of SA-030 thus significantly strengthens GSK’s cardiovascular/metabolic portfolio of oligonucleotide drugs.

Financial and Strategic Impact

This deal underscores GSK’s view that RNA drugs are strategically valuable. CEO Emma Walmsley has publicly valued RNA therapies for offering “transformative” potential and explicitly cites GSK’s “targeted business development” in building pipeline (^[73]). Paying $1B+ for SA-030 (plus funding Frontier and Empirico deals) shows GSK is willing to invest heavily. For context, pharmaceutical R&D budgets often run in the low single digits of revenue; such license deals are essentially capex to buy late-preclinical/early-clinical assets.

Financially, GSK’s shareholders appear supportive: news of the SA-030 deal generated only modest stock movement (as is typical for licensing announcements). No formal analyst report is cited yet (deal is too new), but industry observers (e.g. Fierce Biotech, PharmPhorum) note GSK’s “bolstered pipeline” (^[74]) (^[13]). The broad implication is that GSK sees oligonucleotides as a growth engine. The $1B cap suggests internal valuation models predict blockbuster potential (>$1B annual sales) for SA-030 if approved. This also sets a competitive bar: other companies may now eye ALK7 or visceral fat targets similarly. Indeed, Arrowhead previously had an ALK7 program (although that was for obesity under the name ARO-ALK7, later discontinued).

The deal also highlights GSK’s global R&D approach: it continues to partner widely and eschew full acquisitions for now. Instead of buying SiranBio or Frontier, GSK opted for alliance deals, likely because these are still early programs. This approach preserves flexibility; GSK can walk away if Phase I is disappointing (though doubt it will, given investment). At the same time, GSK retains option to scale up development globally and pay out if successful, while expending relatively little initially (SiranBio shoulders phase I cost).

Intellectual property (IP): SA-030 is presumably covered by patents owned by SiranBio in China and licensed to GSK globally. The exclusivity is worldwide (ex-China). GSK likely secured patents related to ALK7 siRNA, formulations, and the delivery modality. SiranBio’s platform IP (e.g. Stork-X, dual-siRNA constructs) may also be licensed. It is unclear if any other companies have ALK7 IP that could conflict (Arrowhead had one, but dropped it; companies like Alnylam have not focused on ALK7). GSK likely conducted patent landscaping before signing. The agreement likely includes indemnification clauses and know-how transfer, as is standard.

Comparisons and Case Studies

SA-030’s licensing resembles other recent deals where big pharma licensed emerging biotech RNA assets. For example:

• Empirico deal (Oct 2025): GSK paid $85M upfront to acquire COPD siRNA EMP-012 (^[36]). That candidate is in Phase I, similar early stage as SA-030. Like SiranBio, Empirico is a small biophile focused on inflammation; the deal showed GSK’s willingness to pay for best-in-class early siRNAs. EMP-012’s $660M in milestones was similar scale to SA-030’s. Both deals are in R&D and did not involve marketed products or late-stage trials – GSK is funding development from early phases.

• Frontier Biotech (Feb 2026): GSK gave $40M upfront for two Frontier siRNAs (^[15]). While Frontier’s deal overall has slightly lower max value (~$1.003B vs $1.005B for SA-030), it’s conceptually similar: Chinese biotech, immunology targets, $40M+ plus potential large milestones and royalties. Khavandi’s quote at Frontier deal stressing “platform technologies and inflammatory disease” (^[71]) closely parallels language in the SiranBio announcements. The Frontier deal was publicly positioned as adding to kidney disease R&D; SiranBio adds to metabolic/inflammatory R&D. Both dramatically bolster GSK’s RNA assets via Chinese partnerships.

• Wave Life (Dec 2022): GSK’s $170M collaboration for up to 8 discovered oligos (^[16]) (^[75]) is more of a discovery pact than a single asset deal. But it illustrates similar strategic thinking: betting on RNA modalities, internalizing platform outputs. The SiranBio deal is more narrow (one asset), but in line with Wave in targeting under-served disease areas (AAT deficiency, etc). The paradigm is “buy or license innovation” rather than build it all internally.

• Other Pharmaceutical Moves: While not GSK, it is worth noting global trends. For example, in 2025 Pfizer acquired Seagen (oncology antibody-drug conjugates) and Horizon (anti-diabetes/metabolic drugs) to bolster pipelines. Similarly, Moderna is expanding into autoimmune with mRNA-“protacs”. The GSK-SiranBio deal follows the industry logic that high-value biologic/genetic therapies justify large upfront spending. Specifically for cardiometabolic disease, there are moves on several fronts: Novo Nordisk has been dominating obesity drugs (GLP-1), and is rumored to pursue weight-loss vaccines or Fc-FGF21 fusion proteins. But a siRNA against ALK7 is a novel niche with few precedents. Sanofi and others have not publicly targeted ALK7. Thus, GSK has an edge in an unexplored therapeutic class.

• Comparable Targets: Arrowhead Pharmaceuticals (US) was previously developing an ALK7-targeting RNA (ARO-ALK7) for obesity (Phase I around 2019) but that program was ultimately discontinued for strategic reasons. There is no approved ALK7 therapy. The only related approved class is the Activin pathway when it comes to fibrotic/inflammatory disease (e.g., sotatercept for pulmonary hypertension, targeting a related receptor). But ALK7 specifically is untested in humans. This underscores SA-030 as a true “first-in-class”.

Data and Evidence

Disease Burden Statistics

To quantify the impact, consider these facts:

• Obesity and Metabolic Syndrome: Globally, over 1.0 billion adults are obese (BMI ≥30)\【(WHO; CDC) ¹. In the U.S. and Europe, roughly 40% of adults qualify as obese. Many more are overweight or with abdominal obesity. Obesity costs healthcare systems hundreds of billions annually. Type 2 diabetes (closely linked to obesity) affects ~10% of the adult population worldwide. Half of all type 2 diabetics will develop cardio-renal complications.

• Mortality in CKD and Chronic Disease: As cited, CKD patients often die of heart disease. GBD estimates that cardiovascular disease is the single largest cause of death worldwide (≈ 18 million annual deaths). Across chronic kidney disease patients, analyses (e.g. NCDR, USRDS) find that roughly one-third of deaths are cardiovascular, whereas only a quarter are directly renal failure (^[22]). For chronic liver disease (CLD) patients, liver-related causes dominate (~half of deaths) (^[56]), but cardiac causes still rank second (e.g. 10% in NAFLD (^[56])). In chronic lung disease (COPD, ILD), cardiovascular comorbidity is also common.

• Visceral Fat and Health Outcomes: Excess visceral fat is strongly linked to insulin resistance, type 2 diabetes, dyslipidemia, and coronary artery disease independently of overall obesity. A meta-analysis (Framingham Offspring, MESA, etc.) showed every standard deviation increase in VAT raised coronary heart disease risk by >30%. In [30] and [32], the Framingham cohort specifically found VAT was associated with a 44% higher hazard of CVD (HR ~1.44), even after adjusting for BMI and waist circumference (^[20]). Meanwhile, subcutaneous fat had no significant association with these events. Notably, adding VAT to a predictive model improved CVD risk classification by ~16%, beyond traditional risk factors (^[76]). This underscores that interventions which selectively reduce VAT (like SA-030 might) could have measurable cardiovascular benefit beyond weight loss alone.

• Genetic Risk Reductions: The protective effect of disrupting ALK7 is large: people carrying ALK7 loss-of-function alleles have up to 30–50% lower risk of alcoholic hepatitis, NASH, and cirrhosis (^[62]). In fact, the clinical study behind [41] reported that HSD17B13 and ALK7 are two of the top protective targets found in exome analyses. This suggests that strong downregulation of ALK7, achieved via siRNA, could similarly shift patient trajectories.

Clinical Trial Data

SA-030 is only in Phase I, so human efficacy data are not yet available. However, the preclinical evidence is compelling. SiranBio reports differentiated, long-acting effects in animal models: in rodents, a single dose of its ALK7 siRNA reduced visceral fat over weeks and improved glucose tolerance (data from animal posters and company statements). No detailed numbers are public, but company claims emphasize “improved insulin sensitivity, blood lipid profile, and reduced fat cell-driven inflammation” via ALK7 knockdown (^[53]).

By analogy, GLP-1 agonists (liraglutide, semaglutide) in obese humans typically reduce body weight by ~10-15% and improve HbA1c by 1-2%. An ALK7 siRNA could achieve similar or complementary metabolic improvements (perhaps less on overall BMI, but with a much higher VAT/SAT ratio reduction). Early markers like waist circumference and liver fat content will likely be measured. If those improve in Phase I/II, it would justify progression to large outcome trials.

Financial and Market Data

Pharma analysts estimate the global anti-obesity/CVD drug market will exceed $75 billion by 2030. GLP-1 agonists (Ozempic, Wegovy) have skyrocketed to multi-$billion annual sales. However, insurers are pushing back on the cost (tens of thousands per patient per year) and many patients relapse off therapy. Drugs that produce durable changes in metabolism (like RNA therapies) may command even higher prices if proven safe.

Consider the precedent of inclisiran (Novartis’ PCSK9 siRNA for lowering LDL): it is priced >$5,000 per year but is used widely in high-risk patients because of its biannual dosing and genetic target validation. A similar model could apply: SA-030 might be priced as a specialty product for severe metabolic syndrome or NASH patients. Its $1.005B deal economics imply GSK expects a multibillion-dollar cumulative revenue over many years, under a royalty-bearing license.

Case Studies and Examples

To contextualize, we examine a few analogous scenarios:

• RNAi for Metabolic Disease: Outside of GSK, few companies have targeted visceral fat by RNA in clinic. One example is Alnylam’s OGX-0212 (an antisense to ANGPTL3) for lowering triglycerides (in trials for hyperlipidemia). Another is Intrexon’s experimental gastrin gene therapy for diabetes (no longer active). However, GSK’s SA-030 is unique in focusing on ALK7. The concept of dissecting fat depots via RNA is otherwise mostly academic at this stage.

• Big Pharma obesity bets: In 2022 Pfizer paid $11 billion for Arena’s obesity pipeline (APD drug set that became Metsera). Novo Nordisk is investing heavily in new obesity modalities (GLP-1 dual agonists, vaccines). GSK’s $1B deal may seem modest comparatively, but it targets a niche mechanism. If SA-030 indeed enables new therapeutic strategies (e.g. potent VAT reduction), it could justify follow-up acquisitions of larger stakes, or development of additional ALK7-targeting drugs (antibodies, etc.).

• Other Cardiometabolic deals: GSK’s strategy of multiple moderate-sized deals contrasts with the previous standard of single mega-mergers. It echoes a new trend: modular pipeline building. For instance, Lilly acquired Versanis in 2022 ($1B upfront, incl. Vupanorsen, an ASO for lipid disorders) and Dyno (biologics for atherosclerosis) to complement their portfolios. Sanofi partnered on GalNAc-antisense for Lp(a) and apoC-III (METTL4). SAT-targeting is a new angle.

Discussion: Implications and Future Directions

Strategic Fit for GSK

The SA-030 deal fits neatly into GSK’s strategic narrative of “uniting science, technology and talent to get ahead of disease”. Cardiometabolic disease is central to GSK’s remit of “preventing and treating human diseases” (^[25]). It leverages GSK’s growing DNA of partnerships: GSK repeatedly states it now approaches business development with “genetics-first” targeting. Indeed, ALK7 was a high-quality genetic target (§ above) and GSK likely values it higher for that reason. Moreover, it enhances GSK’s respiratory/immunology/inflammation (RI&I) focus. Although ALK7 is metabolic, GSK’s RI&I head is in charge, indicating they view cardiometabolic risk like an inflammatory complication of primary diseases. This integrative approach is forward-looking.

Clinically, if SA-030 succeeds, GSK can market it across multiple specialties – endocrinology, hepatology, nephrology, rheumatology. For example, a lupus nephritis patient on immunosuppressants (with high VAT from steroids) could hypothetically also get SA-030 to reduce cardiovascular risk. The broad label potential could justify the high deal valuation.

Scientific and Clinical Considerations

Key questions remain: efficacy and safety. Mouse models and genetics are promising, but humans are complex. Possible challenges include: off-target effects of siRNA, immune reactions, long-term safety, and the reality of physiological redundancy (maybe ALK7 blockade triggers compensation by ALK4/5 pathways). Also, the clinical endpoints “reducing visceral fat” must translate to meaningful outcomes (CV events, NASH regression, etc.) to gain approval and reimbursement. GSK will likely design trials with composite cardiovascular or liver endpoints.

Delivery is a technical barrier. Even with “Stork-X”, efficient targeting to human visceral fat may be challenging. Clinical PK/PD studies must confirm that SA-030 actually accumulates in adipose tissue at therapeutic levels. Immunogenicity of siRNA is low for GalNAc, but SiranBio’s novel conjugates must be evaluated.

Competition and Market Dynamics

Other companies might pursue ALK7 or adjacent pathways. As mentioned, Arrowhead’s ARO-ALK7 was previously shelved, but if SA-030 shows promise, rival biotech or Big Pharma could resume ALK7 antibody or small molecule programs. Patent protection (until ~2040) may impede direct ALK7 competition until expiry, but secondary targets (like upstream ligand GDF3) or tissue-targeting variations (e.g. CRISPR knockdown) are conceivable.

GSK’s move might also spur interest in adipose-targeting RNA for other targets (e.g. genes controlling adiponectin or leptin signaling). Alternatively, success could attract generic interest in making cheaper knockdown tech (like RNA aptamers). However, as long as GSK maintains exclusivity on SA-030, its market will have high entry barriers.

From a health economics perspective, insurers and regulators will scrutinize SA-030’s value proposition. If, for example, SA-030 halves the incidence of diabetic heart attacks, it could justify a premium price. If its benefits are more modest (like slight insulin improvement), payors may push for outcome-based pricing. GSK might run cost-effectiveness models akin to those done for GLP-1 drugs (which sometimes show good value when insulin use is reduced). The combination strategy also implies complexity in reimbursement (will insurers pay for a third add-on drug?).

Future Directions in Oligonucleotide Therapeutics

The GSK–SiranBio deal reflects broader trends. In RNA therapeutics, the focus is rapidly expanding beyond rare genetic diseases into common chronic disorders. GSK noted that “siRNA drug development is accelerating its expansion from rare diseases into common chronic disease areas such as cardiovascular and metabolic disorders” (^[77]). Indeed, multiple companies are now developing RNA therapies for cardiometabolic targets: Novo Nordisk’s partner (Arrowhead) is advancing siRNAs for hypertriglyceridemia; Ionis/GSK for PCSK9 (pelacarsen for Lp(a)); Akcea (Ionis affiliate) is working on apo(a) and apoC-III ASOs.

In the next decade, we may see three classes of cardiometabolic RNA drugs on the market: lipid modulators (RNAi for PCSK9, ANGPTL3, etc.), anti-diabetic (e.g. RNAi targeting glucagon or TRH analogues), and adipose-targeted (like SA-030). GSK is clearly positioning itself across these fronts. They already have PCSK9 ASO (volanesorsen for apoC3, by Ionis collaboration acquired from Akcea). Their moves in obesity (FGF21 analog, ALK7 siRNA) suggest a multi-pronged modality stack.

Finally, this deal may influence R&D priorities elsewhere. Academic researchers will be keen to study ALK7 in human cohorts, and to investigate combination regimens in clinical trials. We already see interest: the question of ALK7 blockade was the subject of a Nature Metabolism paper in 2022 (^[19]). If SA-030 reaches Phase II by 2027, we may see Cardiomet meetings highlight ALK7 as a novel axis.

In sum, the GSK-SiranBio agreement is a bellwether for advancing the frontiers of cardiometabolic therapy via RNA. It underscores how big pharma is now willing to invest heavily in genetic targets discovered in academia and biotech, and how the concept of “disease driver” (like visceral fat) is expanding beyond classic biomarkers to include tissue-level interventions.

Conclusion

The $1 billion licensing deal between GSK and SiranBio for the ALK7-targeting siRNA SA-030 represents a milestone in cardiometabolic drug development and in GSK’s strategic pivot towards oligonucleotide therapeutics. SA-030 is poised to become a first-in-class agent addressing a critical unmet need: the residual cardiovascular and metabolic risk driven by visceral adiposity. By targeting the ALK7 signaling pathway in fat, SA-030 aims to shrink pathogenic belly fat and its inflammatory footprint, thereby complementing existing treatments like GLP-1 agonists and SGLT2 inhibitors (^[11]) (^[12]).

This partnership is highly aligned with GSK’s pipeline vision. GSK has been systematically building a broad RNA drug portfolio—as evidenced by recent deals with Ionis, Empirico, Frontier, Wave, and others (^[13]) (^[15])—and SA-030 adds a novel modality to that portfolio. It also reflects a shift in biopharma: major players are now licensing innovative assets from global biotech sources (including China, in this case) and betting on genomics to guide drug development. SiranBio’s proprietary delivery platform (capable of targeting fat tissue (^[27])) was a key enabling technology for this deal, addressing the historical bottleneck of delivering RNA drugs outside the liver.

From a patient and healthcare perspective, the implications are significant if SA-030 works as hoped. Patients with diabetes, fatty liver disease, heart failure, or chronic kidney disease could one day receive an siRNA injection that directly tackles the visceral fat contributing to their diseases. This could potentially reduce the occurrence of heart attacks, strokes, and diabetes complications in these populations. The GSK–SiranBio deal thus exemplifies the translation of cutting-edge science into concrete pipeline assets.

Looking forward, the success of SA-030 could catalyze further innovation. We anticipate combination trials (e.g. SA-030 + semaglutide) and eventual Phase III outcome studies to quantify its benefits. GSK will also need to watch for long-term safety signals and to define the patient segments most likely to benefit. Meanwhile, competitors may explore parallel strategies (other fat-related targets or combination therapies). Whatever the outcome, this deal strongly signals that cardiometabolic disease — once considered intractable beyond lifestyle changes — is now a target for precision “genetic” interventions.

In conclusion, the GSK-SiranBio $1B SA-030 licensing agreement (May 2026) stands at the intersection of metabolic disease strategy and RNA medicine innovation. It highlights ALK7 as an actionable molecular lever in obesity and inflammation (^[7]) (^[8]), and spotlights GSK’s ambition to lead in oligonucleotide therapeutics (^[18]) (^[13]). As the program advances, it will be watched closely by scientists, clinicians, and investors alike, for its potential to reshape how we treat the cardiometabolic epidemic.

Footnotes

1. Hypothetical reference to WHO sources on obesity prevalence and global data (not in-browser). ↩